{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:51:43Z","timestamp":1772761903731,"version":"3.50.1"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"FDA Medical Countermeasures Initiative"},{"name":"Intramural Funds from the Center for Biologics Evaluation and Research."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Influenza immune globulin, manufactured from plasma of convalescent or vaccinated donors has been proposed as a potential therapy for severe influenza. In 2009, a program was initiated to collect plasma from donors who self\u2010identified as having had H1N1 influenza or having received the H1N1 pandemic vaccine. The goal of this study was to determine the efficiency of donor screening by self\u2010identification without antibody testing, and to evaluate demographic predictors of high\u2010titer donations.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>Plasma samples from self\u2010identified or control donors were randomly selected to evaluate hemagglutination inhibition (HAI) antibody responses. HAI titers were correlated with donor age, gender, location, and influenza exposure history.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Both self\u2010identified vaccinated and convalescent donor groups had higher geometric mean titers (GMTs) against A\/California\/07\/2009 (H1N1) virus compared to the control donors (39.9, 24, and 8.5, respectively). The proportion of samples with titers \u226564 in vaccinated, convalescent, and control donors were 54%, 37%, and 10%, respectively. Donations with titers \u226416 were predominant in control donors (80%) and substantial in convalescent (47%) and vaccinated (40%) donors. Titers did not correlate with donor age, gender, or geographical location. GMTs for vaccinated donors were significantly higher than for convalescent donors and in both groups significantly higher than in the control.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Targeted collection of plasma containing high levels of anti\u2010influenza antibodies from self\u2010identified donors was effective, but could be further improved by reducing the number of low\u2010titer donations. More selective donor screening and\/or testing for influenza antibodies could increase the potency of an influenza antibody\u2010rich immune globulin (FLUIGIV).<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14530","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T11:08:48Z","timestamp":1518692928000},"page":"1108-1116","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of source plasma from self\u2010identified vaccinated or convalescent donors during the 2009 <scp>H<\/scp>1<scp>N<\/scp>1 pandemic"],"prefix":"10.1111","volume":"58","author":[{"given":"Alexey","family":"Khalenkov","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Reed","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Kreil","sequence":"additional","affiliation":[{"name":"Shire Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McVey","sequence":"additional","affiliation":[{"name":"Baxter BioLife Deerfield Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Norton","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Scott","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy E.","family":"Scott","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,15]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Vaccines and Related Biological Products Advisory Committee transcript of July 23 2009 VRBPAC meeting[Internet] Silver Spring (MD): US Food and Drug Administration;2009. [cited 2017 Jun 8]. Available from:https:\/\/wayback.archive-it.org\/7993\/20170113080614\/http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM175998.pdf."},{"key":"e_1_2_10_3_1","unstructured":"FDA and CDC information on potential \u201cspot shortages\u201d of supplies for treating and preventing novel influenza A (H1N1)[Internet]. Silver Spring (MD): US Food and Drug Administration;2010[cited 2017 Jun 8]. Available from:https:\/\/www.cdc.gov\/H1N1flu\/pharmacist\/."},{"key":"e_1_2_10_4_1","unstructured":"Final estimates for 2009\u201010 seasonal influenza and influenza A (H1N1) 2009 monovalent vaccination coverage [Internet]. Atlanta (GA):Centers for Disease Control and Prevention;2009[cited 2017 Jun 8]. Available from:https:\/\/www.cdc.gov\/flu\/fluvaxview\/coverage_0910estimates.htm."},{"key":"e_1_2_10_5_1","unstructured":"Novel H1N1 flu situation update [Internet]. Atlanta (GA):Centers for Disease Control and Prevention;2009[cited 2017 Jun 8]. Available from:https:\/\/www.cdc.gov\/h1n1flu\/updates\/061909.htm."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003635"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/ciq012","article-title":"Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009\u2010April 2010)","volume":"52","author":"Shrestha SS","year":"2011","journal-title":"Clin Infect Dis"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70318-8"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.167"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1005095"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181d44c1e"},{"key":"e_1_2_10_12_1","first-page":"489","article-title":"Successful treatment of avian influenza with convalescent plasma","volume":"12","author":"Kong LK","year":"2006","journal-title":"Hong Kong Med J"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070359"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002985"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq106"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60493-6"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-8-200610170-00139"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181f127be"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03347.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2907"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30174-1"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2907"},{"key":"e_1_2_10_23_1","first-page":"245","article-title":"Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010","volume":"6","author":"Kubota\u2010Koketsu R","year":"2012","journal-title":"Biologics"},{"key":"e_1_2_10_24_1","unstructured":"PalmerD ColemanM DowdleW et al. Hemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis. Immunology series no. 6 (US Dept. of Health Education and Welfare Public Health Service Center for Disease Control Bureau of Laboratories 1975)."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0029146"},{"key":"e_1_2_10_26_1","unstructured":"Recommendations of the Advisory Committee on Immunization Practices [Internet]. Atlanta (GA):Centers for Disease Control and Prevention;2010[cited 2017 Jun 8]. Available from:https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr59e0729a1.htm."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-70"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00555-10"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-319"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.23.1.66-72.1986"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.040"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/656588"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-414"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907413"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906453"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002081"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3928"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2011.tb04139.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62126-7"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911596107"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.40.19678-en","article-title":"Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October\u2010December 2009","volume":"15","author":"McVernon J","year":"2010","journal-title":"Euro Surveill"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0047"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:53:32Z","timestamp":1695563612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/trf.14530"],"URL":"https:\/\/doi.org\/10.1111\/trf.14530","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,15]]}}}